13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 日本癌学会 JAPANESE CANCER ASSOCIATION

240902EE

Abstracts to be Presented as Poster Presentations

Poster Session D
Wednesday, February 5, 5:30-7:30 p.m.
Mondarchy 5-7

Population Sciences

D01 Assessment of Malnutrition Among Chemotherapy-Naive and Chemotherapy-Experienced Breast Cancer Patients in Ayder Comprehensive Specialized Hospital, Northern Ethiopia, 2024. Samuel G. Asifiha. Mekelle University, Mekelle, Ethiopia.

D02 Natural history of hr-HPV infection and the carcinogenesis of cervical cancer: A two-year follow-up study. Brhanu Teka Endallew. Addis Ababa University, Addis Ababa, Ethiopia.

D03 Improper immune clearance of senescent cells in stagnant lobular involution is linked to increased age-related breast cancer risk. Jaida Lue. Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, United States.

D04 Serum superoxide dismutase activity and colorectal cancer risk by tumor location and sex. Yasushi Adachi. Sapporo Medical University, Sapporo, Japan.

D05 Long-term insulin resistance-promoting diets/lifestyles and colorectal cancer incidence subclassified by tumor pks+ Escherichia coli status. Satoko Ugai. Harvard T.H. Chan School of Public Health, Boston, MA, United States.

D06 Associations of surrogate liver fibrosis assessment and insulin resistance with the incidence of cancer and cardiovascular disease outcomes. Xuehong Zhang. Yale School of Nursing, Orange, CT, United States.

D07 5hmc-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. Jong Park. Moffitt Cancer Center, Tampa, FL, United States.

D08 Progressive lines of treatment increase cachexia risk. Venise Jan Castillon. Memorial Sloan Kettering Cancer Center, New York City, NY, United States.

Data Science

D10 Bayesian Decision Support System for Visualizing The Metastic Risk of Splenic Hilar Lymph Node in Upper Gastric Cancer. Satoshi Takahashi. Division of Medical AI Research and Development, National Cancer Center Research Institute,Tokyo, Japan.

D11 A Blood-Based Biomarker for Reclassifying Malignancy Risk in Indeterminate Pulmonary Nodules Detected in Lung Cancer Screening. Ehsan Irajizad. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

D12 Development of a Novel Urinary Biomarker for Early Detection of Cholangiocarcinoma. Hironori Mizuno. Nagoya University Graduate School of Medicine, Nagoya, Japan.

D13 Multi-objective composite biomarker scores for improved cancer screening. Ana M. Kenney. University of California Irvine, Irvine, CA, United States.

Novel Immunotherapies

D14 Development of allogeneic CAR-T cells with reduced immunogenicity. Chisato Umehara. Keio University School of Medicine, Tokyo, Japan.

D15 Active aldehydes shape the metabolic features of exhausted CD8+ T cells in the tumor microenvironment. Koji Kitaoka. Center for Cancer Immunotherapy and Immunobiology (CCII), Graduate School of Medicine Kyoto University, Kyoto, Japan.

D16 KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment. Tesfahun Dessale Admasu. Cedars Sinai Medical Center, Los Angeles, CA, United States.

D17 Deciphering RIOK2 as a potential target for hepatocellular carcinoma via enhancing tumor immune infiltration. Jian He. Shanghai Jiao Tong University School of Medicine, Shanghai, China (Mainland).

D19 Metabolic Reprogramming of Precursor Exhausted T Cells (Tpex): A Gateway to Improved Adoptively Transferred T cells therapy. Maryam Akrami. Department of Biomedicine, University Hospital Basel, Basel, Switzerland, Switzerland, Basel, Switzerland.

Novel Roles of RNA in Cancer

D20 Revealing the unique malignant mechanism of gastric-type adenocarcinoma of the cervix. Hiroaki Yamada. Kurume University, Kurume, Japan.

D21 Identification and characterization of prognostic isoforms associated with bladder cancer outcomes and development of an isoform-based classifier. Phillip L. Palmbos. University of Michigan, Ann Arbor, MI, United States.

Other

D22 Increased risk of young-onset pancreatic cancer among young adults with obesity, but not underweight. Joo-Hyun Park. Korea University Ansan Hospital, Korea University College of Medicine, Ansan-Si, Korea, Republic of.

D23 Pivotal roles for CaMKK2 and CALML6 in EP4 induced cell migration and metastasis. Soichiro Ishikawa. Yokohama City University, Yokohama, Japan.

D24 Development of an AI-based physical function assessment system using in-clinic movements toward clinical outcome prediction. Nobuji Kouno. National Cancer Center Research Institute, Tokyo, Japan.

D25 Efficacy of LHRHa treatment in luminal type breast cancer and the complexity of cancer cell responses to LHRHa therapy. Muhan Yu. Chiba University, Chiba, Japan.

D27 Estimating divergence times of founder mutations in cancer predisposition genes in the Japanese population using shared haplotype regions. Wataru Nakamura. Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

D28 Sustained anti-tumor effects of BNCT in colorectal cancer: insights from proteomic and pathway Analysis. Jun Arima. Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

D29 Development and validation of a urinary miRNA-based assay for early detection of gastric cancer. Yoriko Ando. Craif Inc., Nagoya, Aichi, Japan.

D30 Impact of the ratio of fecal short-chain fatty acids to lactic acid concentration on the postoperative infectious complications after esophagectomy. Takuya Nagao. Nagoya University Graduate School of Medicine, Nagoya, Japan.

D31 Eribulin Enhances cGAS Activation and Modulates Chromosomal Instability in Triple-Negative Breast Cancer. Mamoru Takada. Chiba University, Chiba, Japan.

D32 CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer. Yuko Kawai. Department of Surgery Keio University School of Medicine, Department of Surgery Tokyo Dental College Ichikawa General Hospital, Tokyo, Japan.

D33 Obesity and the molecular phenotypes of cancer. Ethan Tse. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

D34 The mechanism by which TGF-beta regulates the transcription of claudin4 gene. Etsu Tashiro. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

D35 Exploring the thermomechanical and interfacial behaviors of clay-arabinoxylan nanocomposite for cancer cell culture: A molecular dynamics study. Michael E. Kjelland. Mayville State University, Mayville, ND, United States.

D36 Targeting DNAJA1-mutant p53 axis to suppress epithelial-mesenchymal transition activation and migratory potential in lung adenocarcinoma. Shigeto Nishikawa. Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, MO, Japan.

D37 3D bioprinting using human cancer and stem cells with novel arabinoxylan bioink for 3D cell culture. Michael E. Kjelland. Mayville State University, Mayville, ND, United States.

D38 ASK family kinases regulate cell survival under hyperosmotic stress by sensing proteasome activity. Xiangyu Zhou. Japanese Foundation for Cancer Research, Tokyo, Japan.

D39 RUNX3, MYC and p53 interplay determines metastatic progression. Jungwon Lee. National University of Singapore, Singapore, Singapore.

D40 Extrinsic induction of apoptosis and tumor suppression via the p53- p53PAD7-Hippo-YAP/TAZ-p73 pathway. Rieko Ohki. National Cancer Center Research Institute, Tokyo, Japan.